Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. https://doi.org/10.1038/s41392-021-00487-6.
2. FDA U. Guidance for industry - considerations for the design of early-phase clinical trials of cellular and gene therapy products. https://www.fda.gov/media/106369/download. Accessed 13 Oct 2023.
3. Zhong C, Jiang W, Wang Y, Sun J, Wu X, Zhuang Y, et al. Repeated systemic dosing of adeno-associated virus vectors in immunocompetent mice after blockade of T cell costimulatory pathways. Hum Gene Ther. 2022;33(5–6):290–300. https://doi.org/10.1089/hum.2021.129.
4. Sun K, Liao MZ. Clinical pharmacology considerations on recombinant adeno-associated virus-based gene therapy. J Clin Pharmacol. 2022;62(Suppl 2):S79–94. https://doi.org/10.1002/jcph.2141.
5. Tang F, Wong H, Ng CM. Rational clinical dose selection of adeno-associated virus-mediated gene therapy based on allometric principles. Clin Pharmacol Ther. 2021;110(3):803–7. https://doi.org/10.1002/cpt.2269.